MedTrace Logo

Clinical Trial of Autologous CD19 CAR-T Cells (CNCT19) Therapy for Advanced Hepatocellular Carcinoma

NCT06676982 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2025-12-15

No results posted yet for this study

Summary

A phase I clinical study of the safety and tolerability, efficacy of CNCT19 CAR T-cell therapy in patients with advanced hepatocellular carcinoma hepatocellular carcinoma.

Conditions

Interventions

BIOLOGICAL

anti-CD19 CAR-T

All subjects were intravenous administrated with CNCT19 CAR-T.

Sponsors & Collaborators

  • Juventas Cell Therapy Ltd.

    collaborator INDUSTRY

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Tingbo Liang, Professor · Zhejiang University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-10
Primary Completion
2026-07-30
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06676982 on ClinicalTrials.gov